Regional variation and low BRAF testing rates in patients with stage III/IV melanoma may be explained by the lack of clear guidance on testing during the cohort period, regional differences in population characteristics or more selective testing, but they most likely reflect BRAF testing methods and variation in compliance in sending data between regional laboratories. This evidence concerns the gene BRAF and melanoma.